Satellos Bioscience Inc. Common Stock

Satellos Bioscience Inc. Common Stock

MSLE - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$140.34M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Satellos Bioscience Inc. Common StockSatellos Bioscience Inc. Common Stock-3.2--80%--
$24.00

Target Price by Analysts

262.3% upsideSatellos Bioscience Common Stock Target Price DetailsTarget Price
$5.65

Current Fair Value

14.7% downside

Overvalued by 14.7% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$140.34 Million
Enterprise Value$134.21 Million
Earnings per Share$-20.4
Beta1.17
Outstanding Shares21,183,573

Return

Return on Equity-80.37%ROE
Return on Assets-68.78%
Return on Invested Capital-83.54%

Valuation & Multiples

P/E Ratio-3.17P/E Ratio
PEG-3.39PEG
Price to Sales-Price to Sales
Price to Book Ratio3.31Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT-3.26
Enterprise Value to Net Income-4
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 13, 2026
EPS Estimate
-$0.59
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Next Earnings Call

Expected Date
March 26, 2027
EPS Estimate
-$0.57
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %0.12%▼ 36.76%
Total Invested$221,472▼ 99.63%
Investors Holding4▼ 22.00%

About Satellos Bioscience Inc. Common Stock

14 employees
CEO: Francis Gleeson

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based reg...

Satellos Bioscience Common Stock Insider Information FAQ

Stockcircle tracks 2 top investors with a current 13F position in Satellos Bioscience Common Stock. Holdings come from the latest quarterly 13F filings filed with the SEC.

In the latest 13F quarter on Stockcircle, 1 top investor increased or opened positions and 1 top investor reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.